Avalyn Pharma raises $300m in Nasdaq IPO for fibrosis drugs
Avalyn Pharma has priced its initial public offering on the Nasdaq Global Select Market at $18.00 per share, raising $300 million in gross proceeds from the sale of 16,666,667 shares. The offering was upsized ahead of pricing, and the underwriters hold a 30-day option to purchase up to a further 2.5 million shares, which could lift total proceeds to roughly $345 million. Trading under the ticker AVLN was expected to begin on 30 April 2026, with the offering scheduled to close on 1 May.
Morgan Stanley, Jefferies, Evercore ISI and Guggenheim Securities acted as joint book-running managers. The company has not disclosed a post-IPO use-of-proceeds breakdown by programme, though the prospectus filed with the Securities and Exchange Commission will carry that detail.
The pipeline
Avalyn's strategy is built around re-engineering established antifibrotic medicines into inhaled, lung-targeted formulations — a notably different approach from de novo small-molecule or biologic discovery. Its two lead programmes each repurpose drugs already approved in oral form.
AP01 is an inhaled formulation of pirfenidone, currently in MIST, a global Phase 2b trial in patients with progressive pulmonary fibrosis. The company reports encouraging tolerability and clinical activity from earlier Phase 1b work and an ongoing open-label extension, with data the company says support preservation of lung function relative to historical oral pirfenidone benchmarks.
AP02 reformulates nintedanib for inhalation and is being evaluated in AURA, a global Phase 2 trial in idiopathic pulmonary fibrosis. A third programme, AP03, combines pirfenidone and nintedanib in a single inhaled fixed-dose formulation, positioning Avalyn to pursue dual antifibrotic mechanisms through one device.
Market context and competitive positioning
Pulmonary fibrosis is a high-value rare-disease segment. Oral pirfenidone and nintedanib — marketed by Roche and Boehringer Ingelheim respectively — are the two dominant approved therapies for IPF, yet both carry significant tolerability burdens including gastrointestinal side effects that contribute to discontinuation. Avalyn's core commercial thesis is that delivering the same active ingredients directly to the lungs will reduce systemic exposure and improve the tolerability profile, without requiring entirely new molecular entities to clear regulatory hurdles.
This inhaled-reformulation strategy carries a meaningful regulatory read-across advantage: because pirfenidone and nintedanib have established safety profiles in their oral forms, Avalyn's path through the FDA is likely to focus on tolerability differentiation and clinical activity rather than full de novo efficacy packages. The FDA has shown receptiveness to reformulation approaches in rare respiratory disease, and the IPF indication has received prior Breakthrough Therapy designations for other agents, establishing a precedent for expedited development pathways.
The IPO arrives at a moment when rare respiratory disease has attracted renewed investor interest, partly driven by the success of RNA-based lung delivery platforms and a broadening understanding of fibrotic disease mechanisms. Avalyn's differentiated device-drug combination approach means it sits in a relatively uncrowded niche, though readouts from MIST and AURA will be the defining milestones for the stock in the near term.